Ardelyx Announces Launch of Gut Matters: Discoveries and Innovations, a New Podcast for the IBS-C Patient Community
Ardelyx, Inc. (Nasdaq: ARDX) has launched a new podcast called 'Gut Matters: Discoveries and Innovations' for the irritable bowel syndrome with constipation (IBS-C) patient community. The podcast is co-hosted by Johannah Ruddy, M.Ed., Ardelyx's director of patient advocacy, and Dr. Andrea Shin, a practicing gastroenterologist.
The monthly podcast will feature discussions with patients, caregivers, advocacy leaders, healthcare providers, and gastroenterology experts about the impact of IBS-C. It aims to provide education, hope, and valuable insights for those affected by the condition. The hosts hope to create a safe space where people with IBS-C can find fact-based information and hear relatable stories, empowering patients and their support networks.
The first episode is already available, and interested individuals can subscribe to the podcast on various platforms.
Ardelyx, Inc. (Nasdaq: ARDX) ha lanciato un nuovo podcast intitolato 'Gut Matters: Scoperte e Innovazioni' per la comunità dei pazienti con sindrome dell'intestino irritabile e stitichezza (IBS-C). Il podcast è co-condotto da Johannah Ruddy, M.Ed., direttore della difesa dei pazienti di Ardelyx, e dal Dr. Andrea Shin, gastroenterologo in esercizio.
Il podcast mensile presenterà discussioni con pazienti, caregiver, leader di advocacy, operatori sanitari ed esperti in gastroenterologia riguardo all'impatto della IBS-C. L'obiettivo è fornire educazione, speranza e preziose intuizioni per coloro che sono colpiti dalla condizione. I conduttori sperano di creare uno spazio sicuro in cui le persone con IBS-C possano trovare informazioni basate su fatti e ascoltare storie che possano risuonare, dando potere ai pazienti e alle loro reti di supporto.
Il primo episodio è già disponibile e le persone interessate possono iscriversi al podcast su varie piattaforme.
Ardelyx, Inc. (Nasdaq: ARDX) ha lanzado un nuevo podcast llamado 'Gut Matters: Descubrimientos e Innovaciones' para la comunidad de pacientes con síndrome del intestino irritable y constipación (IBS-C). El podcast es co-presentado por Johannah Ruddy, M.Ed., directora de defensa del paciente de Ardelyx, y la Dra. Andrea Shin, gastroenteróloga en ejercicio.
El podcast mensual contará con discusiones con pacientes, cuidadores, líderes de advocacy, proveedores de salud y expertos en gastroenterología sobre el impacto de la IBS-C. Su objetivo es proporcionar educación, esperanza y valiosos conocimientos para aquellos afectados por la condición. Los anfitriones esperan crear un espacio seguro donde las personas con IBS-C puedan encontrar información basada en hechos y escuchar historias con las que se sientan identificadas, empoderando a los pacientes y sus redes de apoyo.
El primer episodio ya está disponible, y las personas interesadas pueden suscribirse al podcast en varias plataformas.
아르델릭스 주식회사(나스닥: ARDX)가 변비가 동반된 과민성 장 증후군(IBS-C) 환자 커뮤니티를 위한 새로운 팟캐스트 'Gut Matters: Discoveries and Innovations'를 시작했습니다. 이 팟캐스트는 아르델릭스의 환자 옹호 이사인 요한나 루디(Johannah Ruddy), M.Ed.와 내과 전문의인 앤드리아 신 박사(Dr. Andrea Shin)가 공동 진행합니다.
월간 팟캐스트는 환자, 간병인, 옹호 리더, 의료 제공자 및 위장병학 전문가와의 대화를 통해 IBS-C의 영향에 대해 논의할 것입니다. 이 팟캐스트는 이 질환의 영향을 받는 사람들에게 교육, 희망 및 귀중한 통찰을 제공하는 것을 목표로 합니다. 진행자들은 IBS-C 환자들이 사실에 기반한 정보를 찾고 공감할 수 있는 이야기를 들을 수 있는 안전한 공간을 만들기를 희망합니다. 이는 환자들과 그들의 지원 네트워크에 힘을 실어주는 것입니다.
첫 번째 에피소드는 이미 사용 가능하며, 관심 있는 분들은 다양한 플랫폼에서 팟캐스트를 구독할 수 있습니다.
Ardelyx, Inc. (Nasdaq: ARDX) a lancé un nouveau podcast intitulé 'Gut Matters: Découvertes et Innovations' pour la communauté des patients atteints du syndrome de l'intestin irritable avec constipation (IBS-C). Le podcast est co-animé par Johannah Ruddy, M.Ed., directrice de la défense des patients chez Ardelyx, et le Dr Andrea Shin, gastro-entérologue en exercice.
Ce podcast mensuel mettra en avant des discussions avec des patients, des aidants, des leaders de la défense, des prestataires de soins de santé et des experts en gastro-entérologie sur l'impact de l'IBS-C. Il vise à fournir éducation, espoir et perspectives précieuses pour ceux qui sont touchés par cette condition. Les hôtes espèrent créer un espace sûr où les personnes atteintes de l'IBS-C peuvent trouver des informations basées sur des faits et entendre des histoires auxquelles elles peuvent s'identifier, donnant ainsi du pouvoir aux patients et à leurs réseaux de soutien.
Le premier épisode est déjà disponible, et les personnes intéressées peuvent s'abonner au podcast sur diverses plateformes.
Ardelyx, Inc. (Nasdaq: ARDX) hat einen neuen Podcast mit dem Titel 'Gut Matters: Entdeckungen und Innovationen' für die Gemeinschaft der Patienten mit Reizdarmsyndrom und Verstopfung (IBS-C) gestartet. Der Podcast wird gemeinsam moderiert von Johannah Ruddy, M.Ed., der Direktorin für Patientenvertretung von Ardelyx, und Dr. Andrea Shin, einer praktizierenden Gastroenterologin.
Der monatliche Podcast wird Diskussionen mit Patienten, Pflegekräften, Interessenvertretenden, Gesundheitsdienstleistern und Experten für Gastroenterologie über die Auswirkungen von IBS-C beinhalten. Ziel ist es, Bildung, Hoffnung und wertvolle Einsichten für die von dieser Erkrankung Betroffenen zu bieten. Die Moderatoren hoffen, einen sicheren Raum zu schaffen, in dem Menschen mit IBS-C faktenbasierte Informationen finden und relatable Geschichten hören können, die Patienten und deren Unterstützungsnetzwerke empowern.
Die erste Episode ist bereits verfügbar, und interessierte Personen können den Podcast auf verschiedenen Plattformen abonnieren.
- Launch of a new podcast targeting the IBS-C patient community, potentially expanding Ardelyx's reach and brand awareness
- Collaboration with healthcare professionals and experts in the field, which may enhance the company's credibility
- None.
WALTHAM, Mass., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced the launch of Gut Matters: Discoveries and Innovations, a new podcast for the irritable bowel syndrome with constipation (IBS-C) patient community. The podcast is hosted by Ardelyx’s director, patient advocacy, Johannah Ruddy, M.Ed. and practicing gastroenterologist, Andrea Shin, MD. The first episode is out now. Each month, the hosts will be joined by patients, caregivers, advocacy leaders, healthcare providers and other gastroenterology experts to discuss the impact of IBS-C and provide education and hope for those affected.
“People living with IBS-C often feel lonely and stigmatized. We wanted to create a safe space where people with this condition can find fact-based information, hear stories that likely sound like their own, and gain valuable insights that will provide them with hope as well as the tools to better manage their condition,” said Andrea Shin, MD and podcast co-host. “I am really proud to be a part of the Gut Matters: Discoveries and Innovations podcast. Our hope is to empower patients, family members and caregivers by showing them that they are part of a large community.”
Individuals can subscribe to the podcast and keep up on the latest episodes here, or wherever they get their podcasts.
About Irritable Bowel Syndrome with Constipation (IBS-C)
Irritable bowel syndrome with constipation (IBS-C) is a gastrointestinal disorder characterized by both abdominal pain and altered bowel movements, estimated to affect 12 million people in the U.S. IBS-C is associated with significantly impaired quality of life, reduced productivity, and substantial economic burden.
About Ardelyx
Ardelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor). Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin commercializes PHOZEVEL® (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been submitted in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada. For more information, please visit https://ardelyx.com/ and connect with us on X (formerly known as Twitter), LinkedIn and Facebook.
Investor and Media Contacts:
Caitlin Lowie
clowie@ardelyx.com
FAQ
What is the name of Ardelyx's new podcast for IBS-C patients?
Who are the hosts of Ardelyx's (ARDX) new IBS-C podcast?
How often will new episodes of Ardelyx's (ARDX) IBS-C podcast be released?
What is the main goal of Ardelyx's (ARDX) new podcast for IBS-C patients?
